Miscellaneous neurodegenerative disorders:
Indications for RILUTEK:
Amyotrophic lateral sclerosis (ALS).
Take on an empty stomach. 50mg every 12 hours.
Monitor for hepatic injury. Measure serum aminotransferases every month for first 3 months, and periodically thereafter. If ALT ≥5×ULN develops: do not use; discontinue if elevated bilirubin. Risk of neutropenia; monitor for febrile illness. Discontinue immediately if interstitial lung disease develops. Japanese patients. Elderly. Pregnancy. Nursing mothers.
Caution with concomitant hepatotoxic agents (eg, allopurinol, methyldopa, sulfasalazine). May be potentiated by strong or moderate CYP1A2 inhibitors (eg, ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton). Possibly antagonized by CYP1A2 inducers.
Asthenia, nausea, dizziness, decreased lung function, diarrhea, abdominal pain, vomiting, arthralgia, dry mouth, insomnia, pruritus; abnormal liver function tests, hypersensitivity pneumonitis.